business.financialpost.com
GNT Pharma’s Anti-dementia Drug ‘crisdesalazine’ Demonstrates Efficacy in Phase III Clinical Study with Companion Dogs with Dementia
Crisdesalazine demonstrated significant improvement in cognition function in the primary outcome measure Crisdesalazine demonstrated significant improvement in dementia in the secondary outcome mea…